AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2020
Apr 28, 2020
30583_dirs_2020-04-28_bba05039-d5f2-4f20-a209-252950a21880.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2020-04-24
Reporting Person: FUCHS HENRY J (President, Worldwide R&D)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-04-24 | Common Stock | S | 13642 | $95.3374 | Disposed | 109014 | Direct |
| 2020-04-24 | Common Stock | S | 3678 | $96.8492 | Disposed | 105336 | Direct |
| 2020-04-24 | Common Stock | S | 2680 | $97.3184 | Disposed | 102656 | Direct |
Footnotes
F1: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020.
F2: The price in column 4 is the weighted average price. The price actually received ranged from $95.015 to $95.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F3: The price in column 4 is the weighted average price. The price actually received ranged from $96.17 to $97.15. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4: The price in column 4 is the weighted average price. The price actually received ranged from $97.17 to $97.50. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.